BioSpace News Archive

Adicet Bio, Inc., a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases, announced that company management will participate in two upcoming virtual investor conferences in May and June.

Idera Pharmaceuticals, Inc. (“Idera” or the “Company”) (Nasdaq: IDRA) today announced that it will not continue ILLUMINATE-301, the Company’s trial of tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with anti-PD-1 refractory advanced melanoma, to its overall survival (OS) primary endpoint.

Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that it has entered into a new development and commercialization license agreement with Santen Pharmaceutical Co., Ltd. (Santen) for the PRESERFLO™ MicroShunt

The novel study showcases a cancer-like paradigm in cerebral cavernous malformations (CCM), a poorly understood, yet aggressive disease

Serenus.AI ( www.serenusai.com ), an innovative startup developing AI-based solutions to improve medical treatment decisions, obtained a Notice of Allowance from the US Patent and Trademark Office that the application ‘AUTOMATED METHOD AND SYSTEM FOR SCREENING AND PREVENTION OF UNNECESSARY MEDICAL PROCEDURES’

– Positive results suggest potential for an mRNA-based therapeutic to correct ciliary function in patients with PCD due to DNAI1 mutations – – Company expects to advance a lead PCD candidate into IND-enabling studies in 2H 2021

Oculogica , a leader in concussion diagnosis and categorization, with the only FDA-cleared technology that aids in the diagnosis of concussion without a pre-injury baseline test requirement, announced today it has received a U.S. Army Medical Research and Development Command (USAMRDC) grant for $2 million to develop a wearable version of its technology.

Viewpoint Molecular Targeting, Inc. a radiopharmaceutical company developing precision lead-212-based -particle oncology therapeutics and complementary diagnostic imaging agents, today announced the appointment of Charles Link, M.D., FACP to its Board of Directors

Strata Oncology, Inc ., a precision oncology company advancing molecular indications for cancer therapies, today announced the launch of the Strata Assistant TM app for Epic with Kettering Health Network as its first fully integrated user.

First Systematic Literature Review Characterizing the Safety, Humanistic, and Economic Burden of Cremophor-Based Cancer Treatments to be Presented at the 2021 Virtual International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference